[1] |
|
[2] |
MA G, BI S T. Effect of rosuvastatin on vascular endothelial functions and inflammatory factors of patients with type 2 diabetes mellitus and coronary heart disease[J]. Exp Ther Med, 2019, 17(1):332-336. DOI: 10.3892/etm.2018.6923.
|
[3] |
LEE J, HWANG Y C, LEE W J,et al. Comparison of the efficacy and safety of rosuvastatin/ezetimibe combination therapy and rosuvastatin monotherapy on lipoprotein in patients with type 2 diabetes:multicenter randomized controlled study[J]. Diabetes Ther, 2020, 11(4):859-871. DOI: 10.1007/s13300-020-00778-1.
|
[4] |
BAE J C, MIN K W, KIM Y H,et al. Efficacy and safety of fixed-dose combination therapy with gemigliptin (50 mg) and rosuvastatin compared with monotherapy in patients with type 2 diabetes and dyslipidaemia (BALANCE):a multicentre,randomized,double-blind,controlled,phase 3 trial[J]. Diabetes Obes Metab, 2019, 21(1):103-111. DOI: 10.1111/dom.13491.
|
[5] |
SONG A N, ZHANG C, MENG X F. Mechanism and application of metformin in kidney diseases:an update[J]. Biomed Pharmacother, 2021, 138:111454. DOI: 10.1016/j.biopha.2021.111454.
|
[6] |
章超,曹玲玲,沈冬梅,等. 瑞舒伐他汀联合二甲双胍对2型糖尿病患者血糖、血脂、炎症因子及胰岛素抵抗的影响[J]. 中国现代医生,2020,58(24):124-126,130.
|
[7] |
OGURTSOVA K, DA ROCHA FERNANDES J D, HUANG Y,et al. IDF Diabetes Atlas:global estimates for the prevalence of diabetes for 2015 and 2040[J]. Diabetes Res Clin Pract, 2017, 128:40-50. DOI: 10.1016/j.diabres.2017.03.024.
|
[8] |
HONG T P, SU Q, LI X Y,et al. Glucose-lowering pharmacotherapies in Chinese adults with type 2 diabetes and cardiovascular disease or chronic kidney disease. An expert consensus reported by the Chinese Diabetes Society and the Chinese Society of Endocrinology[J]. Diabetes Metab Res Rev, 2021, 37(4):e3416. DOI: 10.1002/dmrr.3416.
|
[9] |
NOMANI H, MOHAMMADPOUR A H, REINER Z,et al. Statin therapy in post-operative atrial fibrillation:focus on the anti-inflammatory effects[J]. J Cardiovasc Dev Dis, 2021, 8(3):24. DOI: 10.3390/jcdd8030024.
|
[10] |
KANNO M, NAKAYAMA M, ZHU W J,et al. Rosuvastatin pretreatment suppresses distant organ injury following unilateral renal ischemia-reperfusion in hypertensive Dahl salt-sensitive rats[J]. Nephrology (Carlton), 2018, 23(11):1046-1054. DOI: 10.1111/nep.13169.
|
[11] |
DAI Y N, HUANG J L, ZENG L H,et al. Comparison of the preventive efficacy of rosuvastatin versus atorvastatin in post-contrast acute kidney injury in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention[J]. Biomedecine Pharmacother, 2020, 128:110336. DOI: 10.1016/j.biopha.2020.110336.
|
[12] |
MORRISON M C, YAKALA G K, LIANG W,et al. Protective effect of rosiglitazone on kidney function in high-fat challenged human-CRP transgenic mice:a possible role for adiponectin and miR-21? [J]. Sci Rep, 2017, 7(1):2915. DOI: 10.1038/s41598-017-02444-2.
|
[13] |
|
[14] |
TOSO A, LEONCINI M, MAIOLI M,et al. A prospective,randomized,open-label trial of atorvastatin versus rosuvastatin in the prevention of contrast-induced acute kidney injury,worsened renal function at 30 days,and clinical events after acute coronary angiography:the PRATO-ACS-2 study[J]. Cardiorenal Med, 2020, 10(5):288-301. DOI: 10.1159/000506857.
|
[15] |
JIANG Z H, ZHANG J, LU Y A. Protective effects and mechanisms of rosuvastatin on acute kidney injury induced by contrast media in rats[J]. Int J Nephrol, 2020, 2020:3490641. DOI: 10.1155/2020/3490641.
|
[16] |
ABDEEN A, ABOUBAKR M, ELGAZZAR D,et al. Rosuvastatin attenuates piroxicam-mediated gastric ulceration and hepato-renal toxicity in rats[J]. Biomed Pharmacother, 2019, 110:895-905. DOI: 10.1016/j.biopha.2018.11.004.
|
[17] |
NARESH S, BITLA A R, RAO P V L N S,et al. Efficacy of oral rosuvastatin intervention on HDL and its associated proteins in men with type 2 diabetes mellitus[J]. Endocrine, 2021, 71(1):76-86. DOI: 10.1007/s12020-020-02472-5.
|
[18] |
BAO S, WANG X, CHO S B,et al. Agriophyllum oligosaccharides ameliorate diabetic insulin resistance through INS-R/IRS/Glut4-mediated insulin pathway in db/db mice and min 6 cells[J]. Front Pharmacol, 2021, 12:656220. DOI: 10.3389/fphar.2021.656220.
|
[19] |
LIN J L, CHEN P S, LIN H W,et al. Real-world analyses of the safety outcome among a general population treated with statins:an Asian population-based study[J]. J Atheroscler Thromb, 2021. DOI: 10.5551/jat.63076.
|
[20] |
TAGUCHI I, IIMURO S, IWATA H,et al. High-dose versus low-dose pitavastatin in Japanese patients with stable coronary artery disease (REAL-CAD):a randomized superiority trial[J]. Circulation, 2018, 137(19):1997-2009. DOI: 10.1161/CIRCULATIONAHA.117.032615.
|